At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed May 11, 2026 at 07:00 ET
Erasca announced a clinical trial collaboration with Merck to evaluate its pan-RAS molecular glue ERAS-0015 in combination with KEYTRUDA for RAS-mutant solid tumors. Merck will supply pembrolizumab at no cost, and Erasca will sponsor the AURORAS-1 study. This is a non-financial collaboration that provides validation for Erasca's pipeline but does not change the company's fundamental outlook.
- Erasca entered a clinical trial collaboration and supply agreement with Merck for ERAS-0015 + KEYTRUDA in RAS-mutant solid tumors.
- Merck is supplying pembrolizumab at no cost; Erasca sponsors the AURORAS-1 study.
- ERAS-0015 is an oral pan-RAS molecular glue with early Phase 1 data showing favorable safety and partial responses at doses as low as 8 mg QD.
- Approximately 2.7 million patients are diagnosed annually with RAS-mutant tumors worldwide.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access